Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
SphingoTec logo — Improving patient outcomes with innovative diagnostics for a...

SphingoTec

Improving patient outcomes with innovative diagnostics for acute care: Actionable insights in real-time

Founded 2002 Germany Hennigsdorf, Germany 30 employees Series B Total: $1.50M Biotechnology

General Information

Company Name SphingoTec
Founded Year 2002
Location Germany Hennigsdorf, Germany
Employees 30
Industries Biotechnology
Funding Stage Series B
Business Model B2B, White Label
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with SphingoTec. To contact SphingoTec, visit sphingotec.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does SphingoTec compare?

A PDF of SphingoTec and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting SphingoTec soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About SphingoTec

Founded in 2002, SphingoTec GmbH is a pioneering player in the Biotechnology sector, based in Germany. The company focuses on developing innovative biomarkers to diagnose, predict, and monitor acute medical conditions such as heart failure, kidney injury, and circulatory shock, with the aim of enhancing patient management and treatment strategies.

Under the leadership of Dr. Andreas Bergmann—renowned for developing the "gold standard" sepsis biomarker Procalcitonin—the company leverages its expertise to spearhead innovations for both acute care diagnostics and prevention strategies addressing long-term health risks like obesity and cardiovascular diseases.

The recent €1.50M Series B investment on 14 March 2023, led by HBM Partners, underscores investor confidence in SphingoTec's capacity to deliver actionable, real-time insights into complex medical conditions. This funding marks a strategic step in bolstering their research capabilities, aiming to revolutionize diagnostic solutions in the acute care space.

Business keywords: innovative diagnostics, acute care, biomarkers, acute heart failure, acute kidney injury, circulatory shock, patient management, treatment strategies, health risk prediction, obesity biomarkers, cardiovascular disease biomarkers, breast cancer biomarkers, sepsis diagnostics, in vitro diagnostics, blood-based protein biomarkers

Services & Products

biomarker development
out-licensing of diagnostic solutions
critical care diagnostics
IVD assay provision

Target Customers

research laboratories pharmaceutical companies critical care units clinicians transplant centers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B €1.50M 1
HBM Partners
HBM Partners
14 Mar 2023
Series B Undisclosed 1
HBM Healthcare Investments
HBM Healthcare Investments
19 Jul 2022
Convertible Note Undisclosed 2
HBM Healthcare Investments HBM Partners
HBM Healthcare Investments, HBM Partners
22 Apr 2022
Convertible Note Undisclosed 1
HBM Healthcare Investments
HBM Healthcare Investments
06 May 2021

SphingoTec Alternatives & Competitors

View All Alternatives
SphingoTec vs
Adrenomed AG
Adrenomed AG Germany

An innovative biomarker-guided precision medicine solution for patients in acute care with sepsis an...

Series E
16 employees
Biotechnology, Pharmaceutical
SphingoTec vs
Astute Medical
Astute Medical

Enhancing rapid diagnosis and risk assessment in acute medical conditions through innovative protein...

Venture round
Biotechnology, Health Care
Compare SphingoTec vs Astute Medical
SphingoTec vs
Vasomune Therapeutics, Inc.
Vasomune Therapeutics, Inc. Canada

Biopharmaceutical leaders developing the next generation of medicine to normalize host vascular resp...

Grant
10 employees
Biotechnology, Health Care
View all alternatives

FAQ About SphingoTec

Improving patient outcomes with innovative diagnostics for acute care: Actionable insights in real-time
SphingoTec was founded in 2002.
SphingoTec is headquartered in Hennigsdorf, Germany.
SphingoTec operates in Biotechnology. Its work centres on innovative diagnostics, acute care, biomarkers and acute heart failure. Its customers include research laboratories, pharmaceutical companies and critical care units.
SphingoTec has a B2B and White Label business model. Its revenue comes from Licensing, Product Sales and Service Fee.
SphingoTec has approximately 30 employees.
SphingoTec has completed 4 funding rounds, raising a total of $1.50M. The latest funding stage is Series B.
SphingoTec offers: biomarker development, out-licensing of diagnostic solutions, critical care diagnostics, IVD assay provision.
Top alternatives and competitors to SphingoTec include Adrenomed AG, Astute Medical, Vasomune Therapeutics, Inc., Kantum Pharma, CardioRenal. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SphingoTec and Adrenomed AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SphingoTec, https://bouncewatch.com/company/sphingotec, updated 14 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes